this issue of theJowrnal, Dr Chan and colleagues provide results from a small randomized clinical trial in women with the polycystic ovary syndrome to determine the effects of weight loss with the use of Chinese green tea. The
study is of interest because it attempts to objectively determine effectiveness of this agent in a specific group of women, many of whom find weight loss a daunting task and are desperate to find remedies for their disorder. I applaud the authors for attempting to evaluate a food supplement for efficacy. While this study is small, and the data may have issues regarding generalizeablity, the study emphasizes the importance ofproviding rigor of evaluation in an area that is quite important to all of us. Unsubstantiated claims have been with us since medicine's early beginnings and I dare say will be around during all of medicine's existence. In the United States, our task to determine efficacy or effectiveness of "alternative choice therapies" has not been made easy subsequent to the 1994 Dietary Supplement Health Education Act (DSHEA), http://www.cfsan. fda.gov/-dms/dietsupp.html, which gives our Food and Drug Administration minimal regulatory control over dietary supplements. The act specifies labeling requirements, yet the safety is left to the manufacturers, and less than 1% of adverse events are ever reported for any of these agents. Canada's National Health Products Regulations Act is ahead ofthe United States; however, many agree that the entire industry suffers from a lack of well-designed methods to determine if these agents work and if they are safe. Our task is likewise complicated by data that suggest that the use of herbal medicines increased 380% in the 1990s. Among adults who take prescription medications, approximately 20% use a herbal medication or a high-dose vitamin and more than 60% of complementary and alternative medicine therapy users do not disclose this to their physician.' Lest we be too critical, how many among us are not without family remedies that have been shown to work by anecdote?
It is important to know when a common remedy does not work because of expense, drug interactions, idiosyncrasy, potential severe harm, and the importance of avoiding false hope.
Without evaluation in groups ofpatients, by relying merely on mechanistic inference, real harm can be done. For example, while a discussion of the cytochrome P450 system is beyond the scope of this editorial, this system is crucial to drug and herbal metabolism.'3 Cytochrome P450 is a family of the body's more powerful detoxification enzymes. Over 60 key Fronm the Department of Obstetnics and Gynecology, Oklahooma University Health Sciences Center, Oklahomia City, OK. forms are known, with hundreds of genetic variations possible, producing a wide variety of susceptibilities to specific toxins.
As the saying goes, "One man's meat is another man's poison."
The system is extremely complicated in that 12 cYP gene families have been identified, frequently two or more enzymes can catalyze the same type of oxidation, and enzymes can be organ-specific, varied, genetically absent, or hyperactive in certain racial groups.
The only effective way to deal with all these sources of variation is through the power of randomization. Randomization offers the opportunity of comparing similar characteristics that are both known and unknown. In short, it reduces selection bias.
The randomized clinical trial format has important weaknesses and this need to be understood. In general, it is not a good way to evaluate harm. The Achilles heel for assessing internal validity is dropouts. Randomized clinical trials measure average effects, usually in select persons, who volunteer and by definition are different from those persons who do not volunteer for such studies. Many times generalizeablity suffers as a consequence. Nevertheless, for therapeutic interventions, the randomized clinical trial, properly conducted, remains the gold standard.
There is so little rigor applied to many ofthe agents commonly used that an entire portfolio ofdesigns is welcomed regarding any ofthese agents because ofthe paucity ofquality studies that address efficacy and risks. Each design has certain advantages and limitations. Many questions will never be answered in this area either because of feasibility, ethics or because of expense.
Chan et al have taken a small step for all of us. We suggest that these investigators widen their efforts and continue to help determine if common remedies are of use. It is just as important to determine when they do not work. There is a wellknown positive results bias as well as a "hot stuff' bias that creeps into our literature, and many argue that it is unavoidable. I was not sure if the Chinese green tea was served hot or cold from reading the manuscript! Multiple confirmatory trials looking at the effects of Chinese green tea, perhaps with differing doses, would be of interest. Regardless, it is refreshing to see these investigators tackle this issue.
